Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer

Published:2020-12 Issue: Volume:495 Page:41-52
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Quan Chuntao,Chen Yuchen,Wang Xiaomu,Yang Dong,Wang Qing,Huang Yixue,Petersen Robert B.,Liu Xinran,Zheng Ling,Li Yangkai,Huang Kun

Funder

Natural Science Foundation of China

HUST

Fundamental Research Funds for the Central Universities

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference54 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA;Bray;Cancer. J. Clin.,2018

2. The quest to overcome resistance to EGFR-targeted therapies in cancer;Chong;Nat. Med.,2013

3. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

4. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study;Shi;Ann. Oncol.,2017

5. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer;Tong;Canc. Lett.,2017

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase Separation of Chromatin Structure-related Biomolecules: A Driving Force for Epigenetic Regulations;Current Protein & Peptide Science;2024-09

2. Role and potential therapeutic value of histone methyltransferases in drug resistance mechanisms in lung cancer;Frontiers in Oncology;2024-03-08

3. Combination of Anti-Angiogenics and Immunotherapies in Renal Cell Carcinoma Show Their Limits: Targeting Fibrosis to Break through the Glass Ceiling?;Biomedicines;2024-02-07

4. Engineered 3D tumor microenvironment recapitulating stiffness of lung tissue to explore drug resistance of lung carcinoma;Journal of Industrial and Engineering Chemistry;2023-11

5. An antioxidant feedforward cycle coordinated by linker histone variant H1.2 and NRF2 that drives nonsmall cell lung cancer progression;Proceedings of the National Academy of Sciences;2023-09-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3